You have 9 free searches left this month | for more free features.

Biliary Cancer

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Cholangiocarcinoma Non-resectable Trial in Chengdu (Candonilimab, Cisplatin, Gemcitabine)

Recruiting
  • Cholangiocarcinoma Non-resectable
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Aug 4, 2023

Liver and Biliary Cancer Patients Treated With PD-1 Combination

Active, not recruiting
  • Hepatocellular Carcinoma
  • Bile Duct Cancer
  • [68Ga]FAPI PET/CT and [18F]FDG PET/CT
  • Beijing, China
    Department of Nuclear Medicine, Peking Union Medical College Hop
Dec 14, 2022

Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct Trial run by the National Cancer Institute (NCI) (oxaliplatin,

Not yet recruiting
  • Biliary Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
May 13, 2023

Observational Monocentric Study on Biliary Tract Cancer (BABEL)

Recruiting
  • Biliary Tract Cancer
    • Roma, Rome, Italy
      Fondazione Policlinico Universitario Agostino Gemelli/IRCSS - UO
    Jul 10, 2023

    Advanced Biliary Tract Cancer Trial in Tianjin (Cadonilimab+Regorafenib+GC)

    Not yet recruiting
    • Advanced Biliary Tract Cancer
    • Tianjin, Tianjin, China
      Tianjin Cancer Hospital Airport Hospital
    Apr 7, 2023

    Carcinoma, Intrahepatic Cholangiocarcinoma, Gallbladder Cancer Trial (HAIC, Surufatinib, Tislelizumab)

    Not yet recruiting
    • Carcinoma
    • +7 more
    • (no location specified)
    Nov 12, 2023

    Biliary Tract Tumors, Gallbladder Cancer, Cholangiocarcinoma Trial in Seoul (Durvalumab + Gem/Cis, Gem/Cis)

    Active, not recruiting
    • Biliary Tract Neoplasms
    • +2 more
    • Seoul, Korea, Republic of
      Asan Medical Center
    Jan 30, 2023

    Advanced Biliary Tract Cancer Trial (H101, Tislelizumab, Lenvatinib)

    Not yet recruiting
    • Advanced Biliary Tract Cancer
    • (no location specified)
    Apr 11, 2023

    Biliary Cancer Trial in San Francisco (Pembrolizumab, Sargramostim)

    Completed
    • Biliary Cancer
    • San Francisco, California
      University of California San Francisco
    Jan 21, 2022

    HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer Trial in Beijing (KN026, KN046, XELOX)

    Not yet recruiting
    • HER2-positive Colorectal Cancer
    • HER2-positive Biliary Tract Cancer
    • Beijing, State*, China
      Peking University cancer hospital & institution
    Aug 2, 2023

    Biliary Tract Cancer Trial (GEN-001, Pembrolizumab, mFOLFOX)

    Not yet recruiting
    • Biliary Tract Cancer
    • (no location specified)
    Aug 16, 2023

    Advanced Biliary Tract Cancer Trial (anlotinib+TQB2450+nab-paclitaxel+cisplatin)

    Not yet recruiting
    • Advanced Biliary Tract Cancer
    • (no location specified)
    Apr 2, 2023

    Biliary Tract Diseases, Gallbladder Cancer, Extrahepatic Bile Duct Cancer Trial (no interventions)

    Not yet recruiting
    • Biliary Tract Diseases
    • +5 more
    • no interventions
    • (no location specified)
    Jun 1, 2023

    LIver, Biliary tRAct and pancReatic Cancers

    Recruiting
    • Liver Cancer
    • +2 more
    • Blood drawing
    • Hangzhou, Zhejiang, China
      The Second Affiliated Hospital, Zhejiang University School of Me
    Nov 14, 2023

    Advanced Biliary Tract Cancer Trial in Shanghai (Sintilimab, Lenvatinib, Cryoablation)

    Recruiting
    • Advanced Biliary Tract Cancer
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Mar 22, 2023

    Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance Study -

    Not yet recruiting
    • Biliary Tract Cancer
      • (no location specified)
      Apr 26, 2023

      Esophageal Cancer, Small Bowel Cancer, Gastroesophageal-junction Cancer Trial in Sacramento (Ablative local therapy)

      Recruiting
      • Esophageal Cancer
      • +10 more
      • Ablative local therapy
      • Sacramento, California
        University of California, Davis
      Oct 27, 2023

      Biliary Tract Tumors, Immunotherapy Trial in Beijing (Durvalumab, Lenvatinib Oral Product, Chemotherapy)

      Recruiting
      • Biliary Tract Neoplasms
      • Immunotherapy
      • Beijing, Beijing, China
        Chinese Academy of Medical Sciences & Peking Union Medical Colle
      Jul 6, 2023

      Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer Trial in Guangzhou (Camrelizumab and Apatinib Plus GP)

      Not yet recruiting
      • Locally Advanced Biliary Tract Cancer
      • Metastatic Biliary Tract Cancer
      • Camrelizumab and Apatinib Plus GP
      • Guangzhou, Guangdong, China
        Cancer center of SunYat-sen University
      Feb 15, 2023

      GI Cancer Trial in Taoyuan (Frailty intervention measures)

      Recruiting
      • GI Cancer
      • Frailty intervention measures
      • Taoyuan, Taiwan
        Chang Gung Memorial Hospital
      Sep 22, 2023

      Biliary Tract Cancer, Immune Checkpoint Inhibitor, Predictive Cancer Model Trial in Beijing (Immune Checkpoint Inhibitors)

      Recruiting
      • Biliary Tract Cancer
      • +2 more
      • Immune Checkpoint Inhibitors
      • Beijing, Beijing, China
        Chinese Academy of Medical Sciences & Peking Union Medical Colle
      Oct 5, 2023

      AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary

      Recruiting
      • Biliary Tract Cancer
      • Blood drawing
      • Guangzhou, Guangdong, China
      • +1 more
      Dec 28, 2022

      Pancreas Cancer Trial (mRNA expression)

      Not yet recruiting
      • Pancreas Cancer
      • mRNA expression
      • (no location specified)
      Aug 8, 2022

      Predict the Response of Biliary Tract Tumors to Immunotherapy

      Recruiting
      • Biliary Tract Tumor
      • Cholangiocarcinoma
      • Blood samples, tumor biopsy specimens will be collected
      • Hangzhou, Zhejiang, China
        Zhejiang Cancer Hospital
      Sep 22, 2023

      Multi-Platform Profiling of Resected Biliary Tract Cancer

      Recruiting
      • Biliary Tract Cancer
      • +7 more
      • Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
      • Chicago, Illinois
      • +1 more
      Jan 23, 2023